Sialylation of bacterial capsules has been proposed as an important virulence factor for several species of encapsulated pathogens, including group B Streptococcus. We have constructed a transposon mutant strain of type III group B Streptococcus that expresses a capsular polysaccharide differing from the wild type only in that the mutant strain's capsule lacks sialic acid. The mutant polysaccharide is antigenically identical to the capsular polysaccharide of type 14 Streptococcus pneumoniae, as predicted by the structures of the type III group B Streptococcus and S. pneumoniae polysaccharides. Loss of capsular sialic acid was associated with loss of virulence in the mutant strain in a neonatal rat model of lethal group B Streptococcus infection. These studies demonstrate directly that capsular sialic acid is a critical virulence determinant for type III group B Streptococcus and support the general hypothesis that surface sialylation aids pathogenic microorganisms in evading host defenses.
The nine-carbon sugar acid N-acetylneuraminic acid, or sialic acid, is found on many biological surfaces, including a variety ofeukaryotic cells and several species ofpathogenic bacteria. The presence of sialic acid residues on the glycosyl portion of surface glycoproteins or polysaccharides appears to have important effects on modulation of cell-cell interactions and, in the case of sialylated parasites, on infectivity and immune response of the host (1) (2) (3) . Sialylation of the surface of a particle, such as a bacterial cell, may inhibit activation of the alternative pathway ofcomplement (4) . Relative resistance to opsonophagocytosis has been associated with a sialylated polysaccharide capsule in Escherichia coli and in group B Streptococcus (GBS), both major bacterial pathogens for human neonates (2, 3) . GBS organisms bearing the native type III GBS capsular polysaccharide have been shown to inhibit direct activation of the alternative pathway of complement, while organisms having an enzymatically desialylated capsule supported complement activation (5) . Thus, sialylation may be an important mechanism by which GBS evades host defenses. In addition, the presence of charged sialic acid residues in the terminal side chain position has been shown to affect the conformation of the type III capsular polysaccharide. Antibodies protective against type III GBS infection are primarily directed against the sialylated polysaccharide and appear to recognize a conformational immunodeterminant fully expressed only in the sialylated, or "native," antigen (6, 7) .
While these observations have provided indirect evidence for the importance of sialic acid in the virulence ofGBS, it has not been possible until now to study directly the role of sialic acid in the pathogenesis of GBS infection. Utilizing transposon mutagenesis, we recently created and characterized an avirulent mutant strain of type III GBS that totally lacked a polysaccharide capsule (8) . Now, we report the construction and immunochemical characterization of a mutant strain of type III GBS that expresses an asialo capsular polysaccharide on its cell surface. Our studies of this mutant strain support the hypothesis that capsule sialylation is an important factor in the pathogenesis of type III GBS infection.
MATERIALS AND METHODS
Antigens and Antisera. Purified type III GBS capsular polysaccharide was prepared from broth cultures of a type III strain as described (6, 7 (8) . Transconjugants deficient in expression of capsule or capsular sialic acid were selected by failure to agglutinate in the presence of wheat germ lectin and by growth on Todd Hewitt agar containing tetracycline (10 ,ug/ml) and streptomycin (750 Ag/ml) (8) .
Immunoblot Analysis. Immunoblot assays were performed as described (8 (12, 13) . This suspension was centrifuged at 4000 rpm for 1 hr. The supernatant was dialyzed against H20, treated with DNase (0.1 mg/ml; Sigma) plus RNase (0.5 mg/ml; Sigma), and then treated with Pronase (1 mg/ml; Sigma), each overnight at 37°C. After dialysis against distilled water, the solution was concentrated to 25 ml and loaded onto a 2.5 x 30 cm column filled with DEAE-Sephacel (Pharmacia), equilibrated with 10 mM Tris-HCL (pH 8.5). The column was washed with 3 bed vol of the same buffer and the eluate was collected as fraction 1. The column was washed with 2 M NaCl in the same buffer and the eluted material was collected as fraction 2. Each fraction was dialyzed extensively against distilled water and lyophilized.
Pn14 ELISA. Pnl4 capsular polysaccharide was coupled to poly-L-lysine (Sigma) and coated onto 96-well plates as described (8, 14) at a polysaccharide concentration of 10 ,tg/ml. After washing three times with 40 mM sodium phosphate (pH 7.0) containing 0.05% Immune Electron Microscopy of Strain COH31-21, Demonstrating an Asialo Capsule. Immune electron microscopy was performed on strains COH31-21, COH31r/s, and COH31-15 by using Pnl4 antiserum. After incubation with Pnl4 antiserum, the bacterial cells were treated with ferritin-conjugated goat anti-rabbit IgG and then processed for electron microscopy. As shown in Fig. 1 , no capsule was visualized on the wild-type strain COH31r/s (Fig. 1A) , or on the unencapsulated mutant strain COH31-15 (Fig. 1B) . However, mutant strain COH31-21 (Fig. 1C) (Fig. 2) , a result identical to that obtained when the unencapsulated mutant strain COH31-15 was treated with type III GBS antiserum (8 (Fig. 3) . Native type III polysaccharide did not form a precipitin line with Pnl4 antiserum.
A Pnl4-specific ELISA inhibition assay (Pnl4 ELISA, described in legend to Fig. 4 ) was used to demonstrate the immunochemical similarity between the capsular polysaccharide from mutant GBS strain COH31-21 and that purified from Pnl4. For these experiments, various amounts of capsular polysaccharide isolated from strain COH31-21 were mixed with Pnl4 antiserum before addition of the serum to ELISA wells coated with Pnl4 polysaccharide. As shown in Fig. 4 DNA-DNA hybridization using 32P-labeled Tn9/6 to probe an EcoRI restriction enzyme digest of COH31-21 chromosomal DNA. EcoRI does not cut within the Tn916 sequence (9) . As shown in Fig. SA , two bands representing Tn916 insertions were present in the COH31-21 chromosome. Confirmation that only two insertions were present was obtained by digesting COH31-21 DNA with HindIll. HindIlI cleaves the Tn9O6 sequence once internally, resulting in two junction fragments (9) . As shown in Fig. 5B , after HindIII digestion, the number of junction fragments hybridizing to the probe confirmed that two copies of Tn916 were present in the COH31-21 chromosome. Mutant strain COH31-15, which contains a single Tn9/6 insertion (8), is shown for compari- including Neisseria meningitidis groups B and C, E. coli K1, and all capsular types of GBS. Several indirect lines of evidence have implicated sialic acid as an important factor in virulence of these organisms. Epidemiologic observations have suggested an association between capsule sialylation and capacity for systemic spread and meningeal invasion (19) . This epidemiologic association has been supported by in vitro experiments demonstrating inhibition of complementmediated phagocytosis by sialylated bacteria. The presence of sialic acid residues on the type III GBS capsule has been shown to prevent direct activation of complement via the alternative pathway; removal of the sialic acid residues from the organisms by treatment with neuraminidase produced particles capable of alternative pathway activation (5) . Although these observations constitute strong circumstantial evidence linking sialic acid to virulence, it has not been possible previously to demonstrate whether the relationship was a causal one rather than simply an association. The current studies represent direct evidence that capsule sialylation plays an important causal role in virulence for type III GBS. The loss of capsular sialic acid through transposon mutagenesis produced an avirulent organism, despite the otherwise unchanged expression of capsular polysaccharide on the mutant strain.
The structural relatedness of the type III GBS and Pnl4 capsular polysaccharides enabled us to use antisera directed against the two organisms to identify mutant strain COH31-21 as one expressing the asialo form of the type III GBS capsule. Immune electron microscopy using Pnl4 antiserum demonstrated remarkable antigen specificity, with clear visualization of the mutant COH31-21 capsule and negligible antibody binding to either the wild-type or unencapsulated strains. The 
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sialylation is an important factor in bacterial pathogenicity. Because two separate Tn916 insertions were detected in the chromosomal DNA of COH31-21, it is possible that other phenotypic characteristics are altered in mutant strain COH31-21; although the formal possibility exists that some other virulence factor might also have been affected in addition to the gene sequence involved in sialylation, we did not detect other phenotypic changes among those screened in this strain (expression of group B antigen, production of CAMP factor, and production of/-hemolysin). Furthermore, the likelihood of a single transposon recipient strain acquiring precisely two Tn916 insertions, in both a sialylation gene and in a gene encoding an unrelated virulence determinant, would be extraordinarily small.
Although strain COH31-21 was less virulent in the neonatal rat than the wild-type strain, we think it likely that the magnitude of the effect of sialylation on virulence of many type III GBS strains may be even greater than that indicated by our studies. By electron microscopy, the wild-type strain COH31r/s from which the mutant strain was derived appears to be relatively poorly encapsulated compared to some other type III strains we have studied (11) . Presumably because of its relatively small capsule, strain COH31r/s is itself less virulent in neonatal rats than several other type III clinical isolates, and it is relatively sensitive to in vitro opsonophagocytosis by complement and peripheral blood leukocytes in the absence of specific antibody. Therefore, although loss of capsular sialic acid was clearly associated with loss of virulence in mutant strain COH31-21, a comparable mutation might result in a more dramatic effect in a more virulent wild-type strain.
A large body of experimental evidence has indicated that the presence of sialic acid residues on the surface of a bacterial cell may inhibit activation of the alternative pathway of complement, may interfere with opsonophagocytosis, and may profoundly affect the antibody binding characteristics of cell-surface antigens. Using transposon insertional mutagenesis, we have created a mutant strain oftype III GBS that expresses an asialo capsular phenotype, thus providing a means to assess directly the importance of capsule sialylation in the virulence of type III GBS. The results of these studies represent compelling evidence that capsule sialylation is a critical factor in pathogenicity of type III GBS and support the more general hypothesis that surface sialylation is an important mechanism by which pathogenic microorganisms may evade host defenses.
